Aleglitazar
From Self-sufficiency
Aleglitazar | |
---|---|
File:Aleglitazar.svg | |
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-
7-benzothiophenyl]propanoic acid | |
Other names Ro-0728804, R-1439 | |
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
CAS number | 475479-34-6 |
PubChem | 10274777 |
SMILES | Script error: No such module "collapsible list". |
style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
Molecular formula | C24H23NO5S |
Molar mass | 437.50812 |
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
Infobox references |
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which is being developed by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is currently in phase II clinical trials.[2]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
- ↑ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
- ↑ ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.